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 2 
Abstract 
 
Formoterol is a frequently prescribed β2-agonist used for the treatment of asthma. Due to 
performance enhancing effects of some β2-agonists, formoterol appears on the prohibited list, 
published by the World Anti-doping Agency (WADA).  Its therapeutic use is allowed but 
restricted to inhalation. Since the data on urinary concentrations originating from therapeutic 
use is limited, no discrimination can be made between use and misuse when a routine sample 
is found to contain formoterol. Therefore the urinary excretion of 6 volunteers after inhalation 
of 18 µg of formoterol was investigated. 
An LC-MS/MS method was developed and validated for the quantification of formoterol in 
urine samples. Sample preparation consists of an enzymatic hydrolysis of the urine samples, 
followed by a liquid-liquid extraction at pH 9.5 with diethyl ether/isopropanol (5/1, v/v ). 
Analysis was performed using selected reaction monitoring after electrospray ionisation. The 
method was linear in the range of 0.5-50 ng/mL. The limit of quantification (LOQ) was 0.5 
ng/mL. The bias ranged between -1.0 and -6.8 %. Results for the urinary excretion show that 
formoterol could be detected for 72 hours. The maximum urinary concentration detected was 
8.5 ng/mL without and 11.4 ng/mL after enzymatic hydrolysis. Cumulative data showed that 
maximum 11.5 % and 23 % of the administered dose is excreted as parent drug within the 
first 12 hours, respectively non-conjugated and conjugated.  
Analysis of 82 routine doping samples, declared positive for formoterol during routine 
analysis, did not exhibit concentrations which could be attributed to misuse. 
 3 
Introduction 
 
Formoterol is a potent long-acting β2-adrenergic agonist and has a pronounced and very 
effective bronchodilating effect [1]. Consequently, it is amongst the most prescribed drugs for 
humans in the treatment of asthma. Besides the desired pharmacological action ,some β2-
agonists produce  side-effects on protein synthesis and lipolysis resulting in anabolic action at 
higher doses [2]. Hence β2-agonists might be misused in sports for the stimulatory effects on 
the respiratory and central nervous system and for growth-promoting action. To control the 
use of β2-agonists, the World Anti Doping Agency (WADA) included them in the list of 
prohibited substances [3] and imposed a minimum required performance level (MRPL) of 100 
ng/mL [4].  
Before the introduction of liquid-chromatography mass spectrometry (LC-MS), the detection 
of β2-agonists in the field of doping analysis was performed by gas chromatography-mass 
spectrometry (GC-MS) [5]. For formoterol N-Methyl-N-(trimethylsilyl)trifluoroacetamide 
(MSTFA) in combination with trimethylsilyl-imidazole (TMSIm) is the preferred choice to 
derivatize all groups including the nitrogen of the β-ethanolamine chain [6]. Monitoring 
formoterol in our laboratory by GC-MS after basic liquid-liquid extraction and derivatisation 
never resulted in an adverse analytical finding (AAF) for this substance.  Liquid 
chromatography-mass spectrometry (LC-MS) has proven to be an effective tool in the urinary 
detection of β2-agonists related to doping control analysis [7-10].  Its application for β2-
agonist-detection in our laboratory since 2007, resulted in numerous urine samples which 
were found to contain formoterol (non published results). 
Because of therapeutic importance, the use of formoterol is widespread and the current (2011) 
situation is that the athlete should have a therapeutic use exemption (TUE). Consequently, 
formoterol is frequently declared on  doping control forms [11]. Because the information on 
urinary concentrations of formoterol after inhalation is limited to one paper describing an 
administration study with 2 volunteers [5],  it is difficult to assign the detected concentrations 
in the routine samples to therapeutic use or to doping misuse.  Therefore, the objective of this 
study was to investigate the urinary excretion of a therapeutic dose of formoterol after 
inhalation. Additionally, concentrations from the excretion study will be compared with those 
observed in routine samples. 
 4 
Experimental 1 
Products and reagents 2 
 3 
Formoterol was obtained from  Novartis ( Ringaskiddy, Ireland) and formoterol-d6 (internal 4 
standard) (IS) from Medical-Isotopes (Pelham, USA). The preparation Oxis (formoterol 5 
fumarate) was from Astra Zeneca (Brussels).  6 
Acetic acid (HOAc) p.a., sodium acetate (NaOAc) p.a., isopropanol, diethyl ether, dipotassium 7 
carbonate (K2CO3), sodium hydrogen carbonate (NaHCO3) and sodium hydroxide (NaOH) were 8 
of analytical grade and were purchased from Merck (Darmstadt, Germany). Methanol (MeOH), 9 
ammonium acetate (NH4OAc) and HPLC grade water were from Biosolve (Valkenswaard, The 10 
Netherlands). Beta-glucuronidase containing 145700 units/mL glucuronidase and  714 units/mL 11 
aryl-sulphatas  from Helix Pomatia was from Sigma-Aldrich (Bornem, Belgium). The buffer (pH 12 
5.2) was obtained by dissolving 136 g NaOAc into 800 mL of aqua bidest. The pH was adjusted, 13 
if necessary, to 5.2 by adding HOAc. Then the final volume was made to 1L. Buffer (pH 9.5) was 14 
prepared by dissolving 45 g K2CO3 and 37 g NaHCO3 in 300 mL of H2O. 15 
 16 
Instrumentation 17 
 18 
The HPLC system consisted of a Surveyor MS-pump and Surveyor autosampler with a 50 µL 19 
sample loop (Thermo, San Jose, CA, USA). Twenty microliter of sample was injected. 20 
Separation was performed on a Zorbax RX C8-column (150x2mm, 5 µm) from Agilent (Diegem, 21 
Belgium). The column was maintained at 35ºC. The mobile phase consisted of water (A) and 22 
MeOH (B), both containing 1 mM NH4OAc and 0,1% HOAc. Gradient elution at a flow rate of 23 
0.4 mL/min was performed as follows: 65% A for 0.5 min decreased to 20% A in 11.5 min and 24 
an increase to the initial condition of 65% A in 0.1 min followed by an equilibration step of 2.4 25 
min before the next injection. Total analysis time per sample was 14.5 min. The LC effluent was 26 
pumped to a Quantum Discovery mass spectrometer (Thermo) equipped with an ESI source, 27 
operated in the positive ionisation mode. The capillary temperature was 350 ºC. The sheath gas 28 
flow rate was set to 50 units. No auxiliary gas was used. The mass spectrometer was operated in 29 
selected reaction monitoring (SRM) mode and transitions are presented in table 1. The precursor 30 
ions were selected in the first quadrupole with a peak width at half maximum (FWHM) of 0.7. 31 
 5 
The scan speed and scan width were maintained at 100 ms and 0.01 amu, respectively. The 32 
collision gas pressure was 1.5 mTorr. 33 
 34 
Sample preparation 35 
 36 
The internal standard (IS)-solution  (50 µL, 100 ng/mL of formoterol-d6 in MeOH) was added to 37 
1 mL of urine, followed by the addition of 1 mL of acetate buffer (pH 5.2) and 50 µl of the 38 
enzyme solution. After 2.5h of incubation at 56°C, 1 mL of carbonate buffer (pH 9.5) was added. 39 
Liquid-liquid extraction was performed by rolling for 5 min with 5 mL diethyl ether/ isopropanol 40 
(5/1). After centrifugation at 1.5 G the organic layer was transferred into a new tube and 41 
evaporated until dry at 40°C under oxygen free nitrogen (OFN).  The residue was dissolved in 42 
200 µL of the initial mobile phase composition.  43 
For the analysis without hydrolysis the addition of the acetate buffer, and the enzyme solution as 44 
well as the incubation were omitted. 45 
 46 
 Method validation 47 
 48 
A six-point calibration curve was generated by spiking blank urine with methanolic formoterol 49 
solutions in triplicate at 0.5, 1, 5, 10, 25 and 50 ng/mL. The ratio’s of target compound product 50 
ion area to IS product ion were plotted versus concentration to obtain calibration curves. 51 
Precision and bias were tested at the lowest, middle and highest calibrator. Precision was 52 
assessed as the percentage relative standard deviation (%RSD) of both repeatability (within-day) 53 
(n=6) and reproducibility (between-day and different analysts) (n=18) for a selected level. 54 
Maximum allowed tolerances for precision can be calculated from the Horwitz-equation RSDmax 55 
= 2(1-0.5logC) (C = concentration (µg/mL) x 10-6). Maximum allowed tolerances for repeatability 56 
and reproducibility were 2/3 RSDmax and RSDmax, respectively [12]. Bias was defined as the 57 
difference between the calculated mean amount and the specified amount as a percentage [13].  58 
The limit of quantification (LOQ) of the method was defined as the lowest concentration where 59 
precision  and bias were within the above mentioned  criteria. Selectivity was tested by analysing 60 
several structurally related and other routinely screened doping agents, including corticosteroids, 61 
anabolic steroids, diuretics, stimulants, narcotics and beta-blocking agents. Specificity was tested 62 
 6 
by analysing 6 blank urine samples as described above to evaluate the presence of endogenous 63 
interferences.  64 
Evaluation of the ion suppression was achieved by extracting 6 blank urines following the 65 
aforementioned procedure without the addition of formoterol and IS-solution. After evaporating 66 
the organic solvent, the 6 tubes, containing the extracted matrix and an additional tube 67 
(=reference) were spiked with formoterol at 10 ng/mL and with 50 µL of the internal standard 68 
solution. After evaporating the methanolic solutions, the remaining residues were dissolved in 69 
200 µL of the initial mobile phase and analysed. Then, the ion suppression was determined by 70 
comparing the peak areas for formoterol in the extracted urine samples with the peak area for 71 
formoterol in the reference sample. To evaluate the corrective effect of the IS on the ion 72 
suppression, area ratio’s of formoterol and the IS were compared with the area ratio of formoterol 73 
and the IS in the reference sample.  74 
 75 
Excretion study 76 
 77 
The study was performed with 6 healthy male volunteers aged  23, 28, 29, 31, 34 and 39. The 78 
study protocol was reviewed and approved by the ethical committee of the Ghent University 79 
Hospital (UZGent, Project  B67020072141). Each volunteer signed a statement of informed 80 
consent and inhaled 18 µg formoterol (2 puffs of 9 µg ) using an Oxis Turbohaler. Urine samples 81 
were collected before (0 h) and quantitatively at 1, 2, 3, 6, 9, 12 hours after intake. Additional 82 
samples were collected after 24, 36, 48 and 72h. All urine samples were stored at -20°C awaiting 83 
analysis. Volume and pH were measured and all samples were analysed in duplicate.  84 
 85 
Collection of routine samples 86 
 87 
During a one year period doping control samples in which formoterol was detected during routine 88 
doping analysis were collected and stored at -20°C awaiting analysis.  89 
 90 
 91 
 92 
 93 
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Results and discussion 94 
Method development 95 
 96 
As already stated in the introduction LC-MS is the preferred detection technique for β2−agonists. 97 
The excellent LC-MS sensitivity of formoterol can be attributed to the presence of the basic 98 
nitrogen which is easily protonable during the electrospray ionisation, resulting in abundant 99 
precursor ions.  MS/MS fragmentation of formoterol results in specific product ions which were 100 
explained by Thevis et al. [7]. Due to the amphoteric character of β2-agonists (phenolic hydroxyls 101 
and amine function) the optimal extraction pH can differ for this class of compounds [2]. Henze 102 
et al. investigated the extraction behaviour of β2-agonists thoroughly [14]. Formoterol showed a 103 
quasi constant extraction behaviour between pH 5 and 11.  Because extraction buffers between 104 
pH  9-10 are routinely used in doping control laboratories and have proven to result in clean 105 
extracts for the determination of  β2-agonists [5], a buffer at pH 9.5 was preferred.  106 
According to the literature, β2-agonists can be both excreted free, glucuronidated and sulphated 107 
[2,15].  Therefore β-glucuronidase containing also aryl-sulphatase activity was selected to 108 
hydrolyse the samples. Nevertheless, formoterol is predominantly excreted in urine conjugated as 109 
glucuronides [16-18].  According to Rosenborg et al. [17]  only 4.8% of an administered dose of 110 
formoterol and deformylated formoterol  are excreted in urine as 4’OH-sulphate metabolites.  111 
 112 
Method validation 113 
 114 
Using a least square fit, good linearity (r2 ≥ 0.98) was observed. The calibration curve was not 115 
forced through the origin and for the regression calculation a weighing factor of 1/x was used for 116 
all data points.  117 
The results for precision and bias are summarised in Table 2 and did not exceed 2/3 RSDmax or 118 
RSDmax neither for repeatability nor reproducibility. Deviation of the mean measured 119 
concentration from the theoretical concentration (bias) was below the acceptable threshold of 120 
15% and 20 %  for all levels in the range of the calibration curve [13]. The limit of quantification 121 
(LOQ) of the method was 0.5 ng/mL.  122 
Regarding the selectivity, interferences from other monitored doping agents could not be found. 123 
In addition analysis of 10 different blank control urine samples did not result in the detection of 124 
 8 
interfering substances, proving the specificity of the method.  125 
Determining the ion suppression showed an average value of 30 % with an RSD of  19 % across 126 
the six urine samples. This high average value can be explained by the relatively large amount of 127 
matrix extracted by the diethyl ether/isopropanol mixture.   128 
  The RSD of 19 % indicates a high variation of the ion suppression depending on the individual 129 
samples. This observation requires the correction by an adequate internal standard in order to 130 
obtain correct quantification. After correcting the areas of formoterol with the areas of the 131 
deuterated IS, the effect of the ion suppression was reduced to -3.4 % with an RSD of 3.5 %.  132 
 133 
Application to excretion urine samples 134 
 135 
For all volunteers formoterol could be detected already 1 hour after intake (Figure 1). The 136 
maximum urinary concentration was reached between 1 and 3 hours. The peak concentrations 137 
ranged between 1 ng/mL and 8.3 ng/mL without hydrolysis (Figure 2) and between 2.3 and 11.4 138 
ng/mL with hydrolysis (Figure 3). The observed concentrations in this study are in agreement 139 
with the concentrations observed by Ventura et al. [5] which describe maximum urinary 140 
concentrations of 8.5 and 17.5 ng/mL for two volunteers, respectively, after inhalation of 24 µg 141 
formoterol.    142 
With hydrolysis, detection times reached up to 72 hours for some volunteers whereas without 143 
hydrolysis step the detection time was limited to 36 hours for all volunteers.  144 
The cumulative excretion profiles are presented in figures 3 and 4. The total amount of 145 
unchanged drug excreted during the first 12 hours varied between 1.1 and 2.0 µg without 146 
hydrolysis (Figure 4) and 2.5 and 4.3 µg with hydrolysis (Figure 5) corresponding to 6.3  147 
to 11.5 % and 14 to 23 % of the administered dose, respectively. These results are in agreement 148 
with a previous paper describing that 8 % of an inhaled dose is recovered in urine as free 149 
formoterol [19] and 35% for the total fraction (both free and glucuronides)[17]. 150 
Also the difference observed in the amounts excreted free and  conjugated is in accordance with 151 
previous work, which describe that formoterol is predominantly excreted conjugated more 152 
specific as glucuronides [16-18]. Large individual differences were found in the urinary 153 
concentrations as well as the excreted amounts. This variation can be assigned partially to the 154 
urinary pH and the urinary  flow, which can influence the excretion of basic compounds [20]. 155 
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However, it can not be excluded that the variations are also caused by a poor use of the inhalation 156 
device [21].  157 
 158 
 159 
Application to routine samples 160 
 161 
During a one year period routine samples, in which formoterol was detected, were collected to 162 
determine the urinary concentrations and compare these with the ones obtained from the 163 
excretion study. A total of 7045 samples were screened and 82 samples were found to contain 164 
formoterol (1.1 %). Nearly twice as many samples containing formoterol were detected compared 165 
to a previous study where salmeterol was monitored [8]. Indeed, formoterol is the most popular 166 
β2-agonist used for the treatment of exercise induced asthma. 167 
The histogram showing the distribution of the detected concentrations is presented in figure 5. 168 
The highest detected concentration was 20.8 ng/mL whereas in the excretion study the maximum 169 
observed concentration was 11.4 ng/mL (Figure 6). 170 
The concentrations obtained in our study are obtained after a normal day dose of 2 inhalations. 171 
Taking into account that the dose can be increased to 6 inhalations (= total daydose of 54 µg per 172 
day) in severe cases of asthma [22], the sample in which 20.8 ng/mL was detected can be the 173 
result of such a situation. 174 
Besides, if misuse of formoterol would be widespread or higher therapeutic doses would be used 175 
much more routine samples would show concentrations higher than those obtained during the 176 
excretion study. 177 
 178 
Conclusion 179 
 180 
A sensitive LC-ESI/MS/MS method for the quantification of formoterol in urine was developed 181 
and validated.  The method was successfully applied to urine samples from an administration 182 
study and to urine samples collected during routine analysis. The results of the excretion study 183 
show that after inhalation of 18 µg formoterol, the parent substance could be detected up to 72 184 
hours. The peak concentrations in urine were between 2.3 and 11.4 ng/mL. Excreted amounts 185 
show that  inhaled formoterol is predominantly excreted conjugated. Taking into account the in 186 
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this study observed maximum concentration, the current WADA MRPL of 100 ng/mL is too high 187 
to detect inhaled formoterol after therapeutical application. Comparison of the urinary 188 
concentrations obtained during the excretion studies with the concentrations in routine doping 189 
samples did not allow to conclude that formoterol is misused by athletes for its performance 190 
enhancing effects.  191 
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Legends to figures: 281 
 282 
Figure 1: Extracted ion chromatograms for a blank sample before inhalation (b), urine sample 1h 283 
after inhalation of 18 ùg formoterol (c). transitions 345=> 121 and 149 are for formoterol, 284 
transition 351 => 155 are for formoterol-d6. 285 
 286 
Figure 2: Concentration profiles of excreted formoterol analysed without hydrolysis 287 
 288 
Figure 3: Concentration profiles of excreted formoterol analysed with hydrolysis 289 
 290 
Figure 4: Cumulative excretion curves of formoterol (0-12h) analysed without hydrolysis 291 
 292 
Figure 5: Cumulative excretion curves of formoterol (0-12h) analysed with hydrolysis 293 
 294 
Figure 6: Histogram showing distribution of detected formoterol concentrations in 82 routine 295 
samples. 296 
 297 
 1 
Table 1: MS/MS detection settings for formoterol and formoterol-d6 
[M+H]+ CE DI TLV 
345 
35 93 123 
54 106 123 
34 121 123 
36 134 123 
19 149* 123 
351 19 155 123 
CE: collision energy, DI: diagnostic ion, TLV : Tube Lens Voltage, *quantifier ion 
 
 
Table 2: Bias, repeatability, reproducibility and tolerance limits of the LC-MS/MS method 
including the lowest and highest point of the calibration curves. 
 
Conc 
(ng/mL) 
Repeatability  
Bias  
(%) 
Reproducability  
Bias 
 (%) 
Repeatability 
RSD (%) 
Reproducibility 
RSD (%) 
RSDmax 
(%) 
2/3RSDmax 
 (%) 
0.5 -1.0 -6.8 17.1 13.3 48 32 
10 -0.8 -2.9 1.8 2.0 32 21 
50 -0.05 -0.3 1.6 1.0 25 16 
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